Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience

EŞKAZAN A. E., Ozmen D., ÖZTAŞ M., Bektas F., Bayraktar E. A., Sadri S., ...Daha Fazla

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, cilt.21, sa.8, ss.549-557, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 21 Sayı: 8
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1016/j.clml.2021.04.005
  • Dergi Adı: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.549-557
  • Anahtar Kelimeler: Age, Charlson comorbidity index (CCI), Comorbidity, Chronic myeloid leukemia, Imatinib, CLINICAL CHARACTERISTICS, CML, AGE, COMORBIDITIES, IMPACT
  • İstanbul Üniversitesi Adresli: Evet

Özet

We retrospectively compared the efficacy and safety of frontline imatinib between elderly patients (>= 60 years old) and younger patients ( <60 years old) with chronic myeloid leukemia (CML). Response rates were similar in both groups. Event-free survival was comparable, and overall survival-when non-CML-related deaths were censored-was also similar. Age at diagnosis and the Charlson comorbidity index were significantly associated with overall survival. In the era of tyrosine kinase inhibitors, survival of patients with CML is determined more by comorbidities than by the disease itself.